Administration of Long-Acting Injections by Noel, Christopher & Williams, Karl
St. John Fisher College 
Fisher Digital Publications 
Pharmacy Faculty/Staff Publications Wegmans School of Pharmacy 
4-2018 
Administration of Long-Acting Injections 
Christopher Noel 
St. John Fisher College, cnoel@sjfc.edu 
Karl Williams 
St. John Fisher College, kwilliams@sjfc.edu 
Follow this and additional works at: https://fisherpub.sjfc.edu/pharmacy_facpub 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
How has open access to Fisher Digital Publications 
benefited you? 
Publication Information 
Noel, Christopher and Williams, Karl (2018). "Administration of Long-Acting Injections." NYS Pharmacist 
April 2018, 22-24. 
Please note that the Publication Information provides general citation information and may not be 
appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit 
http://libguides.sjfc.edu/citations. 
This document is posted at https://fisherpub.sjfc.edu/pharmacy_facpub/306 and is brought to you for free and 
open access by Fisher Digital Publications at St. John Fisher College. For more information, please contact 
fisherpub@sjfc.edu. 
Administration of Long-Acting Injections 
Abstract 
Expanding the scope of pharmacy practice demonstrates that the profession has been successful at 
improving public health. Despite being a late adopter, New York's limited experience with vaccines has 
improved immunization rates and lowered rates of disease. During emergencies, the 2017-2018 flu 
season for example, the state has turned to pharmacists to go beyond what the pharmacy practice law 
permits, in this case enabling immunizations in pediatric patients.1 This illustrates recognition of 
untapped potential within the profession to contribute to the public health. Another opportunity for 
pharmacists to enhance the public health is embodied in a Bill introduced in the New York State 
Legislature that would amend the pharmacy practice law to enable administration of "long-acting 
injectables" designed to treat mental health disorders including schizophrenia and substance use 
disorder ("SUD"). The goal of this paper is to review the proposed amendment, the relevant background, 
and to discuss the implications for patients and the pharmacy profession. 
Disciplines 
Pharmacy and Pharmaceutical Sciences 
Comments 
Published by the Pharmacists Society of the State of New York. Inc.: https://pssny.site-ym.com/ 
Posted with permission. 
This article is available at Fisher Digital Publications: https://fisherpub.sjfc.edu/pharmacy_facpub/306 
Temporary Printing Window https://view.flipdocs.com/?ID=10017506_935238&P=0#24
22 of 28 11/29/2018, 5:47 PM
Administration of Long-Acting Injections 
Christopher Noel, PharmD BCPP, Wegmans School of Pharmacy, and 
Karl Williams, RPh, LLM, JD, Wegmans School of Pharmacy 
Expanding the scope of pharmacy practice demon-
strates that the profession has been successful at improv-
ing public health. Despite being a late adopter, New 
York's limited experience with vaccines has improved im-
munization rates and lowered rates of disease. During 
emergencies, the 2017-2018 flu season for example, the 
state has turned to pharmacists to go beyond what the 
pharmacy practice law permits, in this case enabling im-
munizations in pediatric patients.' This illustrates recogni-
tion of untapped potential within the profession to con-
tribute to the public health. Another opportunity for phar-
macists to enhance the public health is embodied in a Bill 
introduced in the New York State Legislature that would 
amend the pharmacy practice law to enable administra-
tion of ·1ong-acting injectables· designed to treat mental 
health disorders including schizophrenia and substance 
use disorder ("SUD'). The goal of this paper is to review 
the proposed amendment, the relevant background, and 
to discuss the implications for patients and the pharmacy 
profession. 
The Legislation 
Assembly Bill A08661, sponsored by Assemblyman 
John McDonald, explains the thinking behind this proposal 
in its •Justification" section. New York is among a minority 
of states (eleven) that does not permit pharmacists to ad-
minister ·non-vaccine items· such as long-acting injec-
tions ('LAls") for mental health disorders. Lack of adher-
ence to oral forms of medication is one of the key reasons 
cited for this legislation. Inability, or unwillingness, to take 
medication as prescribed results in clinical relapse, patient 
suffering, and high rates of readmission to facilities for 
inpatient care. Non-adherent patients are five-times more 
likely to require additional inpatient care than adherent 
patients. The justification further explains that community 
pharmacies are ideal partners in the care of these patients 
because the better proximity to, and accessibility by pa-
tients. Perhaps less intuitive, but more important, there is 
a stigma associated with reporting to a mental health clin-
ic periodically for medication. No such stigma attaches to 
community pharmacies. 
The Bill amends Article 137 of the Education Law relat-
ing to the practice of pharmacy by expanding those med-
ications that pharmacists may provide under the definition 
of •Administer•. Currently limited to a very short list of 
vaccines, the proposal creates a new subsection (6802(22) 
(b)) that includes: ·medications for the treatment of men-
tal health and substance use disorder, as prescribed or 
ordered by a licensed prescriber in this state and in ac-
cordance with regulations promulgated by the commis-
sioner in consultation with the board of pharmacy." 
In addition, the Bill would add a new subdivision, six, 
to the 'Definition of pharmacy practice·. Section 6801(6) 
explicitly states that a •licensed pharmacist may administer 
injectable medications for mental health and substance 
use disorder: 
Schizophrenia 
Schizophrenia is a serious and disabling mental illness 
that affects 1.1% of the US population.2 The first antipsy-
chotic medication was introduced in the 1950s; shortly 
thereafter, it was clear that adherence to these medica-
tions was a major issue. In the mid-late 1960s, the first 
long-acting injectable (LAI) antipsychotic was intro-
duced--however, buy-in was not universal as some were 
skeptical of increased side effects, lack of efficacy, and 
questions of the ethics of this dosage formulation.3 
Patients and doctors have a wide variety of attitudes 
regarding the use of LAI antipsychotics. There is a more 
negative attitude held by treating clinicians, especially in 
those recently diagnosed with schizophrenia versus more 
chronic patients. A European study determined that, of 
nearly 900 healthcare professionals (physicians and nurs-
es) surveyed, 40% preferred LAls in first-episode psychosis 
(FEP) where 90% would prefer them in patients who have 
had two to five psychotic episodes.4 Patients may have 
negative attitudes about LAls as well, but this may be due 
to a lack of information coming from their provider. In 
one study, when an LAI was offered to an LAI-naive pa-
tient, more often the response was neutral or favorable 
(63%) versus unfavorable (37%).' Multiple studies have 
confirmed that attitudes toward LAI antipsychotics is ma-
jorly dependent on previous exposure-many patients 
who have tried LAls prefer this treatment over oral medi-
cations as they •feel better•, have a more ·normal life• and 
find the injections ·easier to remember".2 Other ad-
vantages that LAls have over oral medications that are 
supported by the literature are the lack of need for daily 
administration, transparency of adherence, a lower likeli-
hood of relapse rates and rebound symptoms, reduced 
peak-trough plasma levels, and improved patient satisfac-
tion and outcomes.? 
LAls have gained favor in the eyes of clinicians and 
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patients. These are now starting to be recommended for 
those experiencing first-episode schizophrenia (FES) and 
are regularly recommended for those with chronic multi-
episode schizophrenia or adherence issues (Table 1). 
IABLE..1 PORT2009 WSF8P2012 
FES Oral SGA CJ{ FGA (not Oral SGA > 
CLOZorOLZ) Oral FGA 
Failure of two CLOZ CLOZ 
antipsychotics 
long tenn LAI LAI 
maintenance or non-
adherence 
Substance Use Disorder 
Substance use disorder, opioids in particular, continues 
to be one of the most vexing diseases, resulting, since 
1999, in escalating morbidity and mortality. Despite broad 
recognition, the epidemic continues to advance. In No-
vember 2017, the Centers for Disease Control reported that 
nationwide data for the period October 2015 through Oc-
tober 2016 showed fatal overdoses continued to increase, 
killing over 42,000 people - a five-fold increase over 1999, 
and netting out to more than 600,000 people.6 Chillingly, 
this represents 115 deaths each day. 
Medications available to treat opioid use disorder are 
methadone, buprenorphine, and naltrexone - all of which 
come in various dosage formulations with only certain for-
mulations proving to be more efficacious than placebo in 
controlled studies. Methadone, the most widely studied 
and used medication for opioid use disorder, comes in 
tablet and liquid formulations; it has been shown to reduce 
illicit opioid use, treat opioid use disorder, and retain pa-
tients in treatment better than placebo or no medication.7 
Two medications available as a LAI and focused on herein 
are extended-release (monthly) subcutaneous injectable 
buprenorphine and extended-release (every 4 weeks) in-
tramuscular naltrexone. 
Buprenorphine retains patients in treatment and re-
duces illicit opioid use better than placebo.6 Compared to 
methadone's full mu-agonist properties, it is a partial ago-
nist with a ceiling effect, which makes it less likely to cause 
respiratory depression and safer in overdose (although not 
free of risk in overdose situations). The monthly subcutane-
ous injectable formulation of buprenorphine is FDA-
approved for moderate to severe opioid use disorder in 
patients who are started on transmucosal buprenorphine 
for at least 7 days. The medication is injected into the sub-
cutaneous tissue of the abdomen of the patient at a dose 
of 300 mg for the first two months, and then 100 mg 
monthly thereafter. Extended-release naltrexone is more 
effective than placebo in reducing risk of return to opioid 
use and is proven to be non-inferior to daily buprenor-
phine in terms of treatment retention and reduction of illicit 
opioid use in a 12-week Norwegian trial (n=159). It is FDA-
AFPBN2013 NICE2014 C8ilicliii 2017 
LAI SGA Antipsychotic decided by Antipsychotic decided by 
patient and doctor together patient and doctor 109ether 
N/A CLOZ CLOZ 
LAI LAI Maintenance: 
Oral or LAI depending on 
patient-preference 
approved to prevent return to opioid dependence follow-
ing medically supervised opioid withdrawal. The medica-
tion is injected into the muscle of the upper outer quadrant 
of the gluteal area at a dose of 380 mg every 4 weeks. In-
terestingly, a Cochrane review (13 trials, n=l, 158) concluded 
that oral naltrexone was not superior to placebo in treat-
ment retention or il licit opioid use reduction. 
In December 2016, the National Alliance of State Phar-
macy Associations (NASPA) and the College of Psychiatric 
and Neurologic Pharmacists (CPNP) gathered to specifical-
ly discuss pharmacist administration of LAls.8 In addition to 
these and other pharmacy organization representatives, 
there were representatives from the American Psychiatric 
Association, the Department of Defense, the Substance 
Abuse and Mental Health Service Administration, the Na-
tional Alliance on Mental Illness, and the United States 
Public Health Service, among others.9 The unmet need to 
provide patients increased access to these medications was 
addressed. When it comes to those diagnosed with schizo-
phrenia, about half are not taking their medications as pre-
scribed. For this reason, LAls have gained favor but certain 
barriers remain including scheduling challenges, limited 
personnel and inventory in clinics, reimbursement issues, 
and lack of transportation for the patient to and from the 
clinic. The conclusions of the stakeholder meeting were 
that 1) pharmacists can play a vital role in the effort to im-
prove patient access to these medications and 2) states 
that do not currently have legislation for pharmacist ad-
ministration of LAls should consider incorporating new pol-
icies. 
Discussion 
This amendment to the pharmacy practice law comes 
at a time that the pharmacy profession here in New York is 
well-positioned to help address the medication adherence-
related public health issues identified in the Bill. Viewed as 
a public health resource, the profession has developed the 
'infrastructure' to fulfill the goals of the A08661. In 2008 the 
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scope of practice expanded to permit pharmacists to ad-
minister a short list of vaccines. In response, pharmacy 
schools, the profession, and the Board of Pharmacy mobi-
lized to provide additional education and training neces-
sary to administer these injectable products safely and ef-
fectively. As a result, the framework is in place to include 
additional medications and disease states envisioned in the 
Bill. Training would include medication-specific information, 
the patient-specific counseling, and other aspects of care. 
These are now cornerstones of our profession. 
Assembly Bill A08661 will only narrowly expand the list 
of those medications that trained pharmacists can adminis-
ter. While it is intuitive that A08661 will improve the public 
health as intended in connection with schizophrenia, it 
could go further. 
Thirty-nine states permit pharmacists to administer any 
medication. For example, in Kentucky the ' Practice of Phar-
macy' includes sweeping language permitting 
"administration of medications or biologics in the course of 
dispensing or maintaining a prescription drug order:t0 Al -
so, seven states currently permit pharmacists to prescribe 
controlled substances.11 The Drug Enforcement Administra-
tion characterizes pharmacists in these states as 'mid-level 
practitioners'. With help from Congress and New York 
State pharmacists could work collaboratively with other 
heallh professions, prescribing buprenorphine under proto-
col permitting profoundly greater access to necessary care. 
(ED artide continued from page 5) 
New Legislation 
PSSNY has developed bill language very similar to 
the Governor's budget proposal last year that would 
register and license PBMs. We are in conversations with 
Assembly member Gottfried and Senator Hannon to 
negotiate language acceptable to both houses and to 
identify bill sponsors. Once the budget passes, this will 
be PSSNY's top priority. 
Influence of Media Coverage 
PSSNY has retained a consultant to build a media 
presence that has helped us get to where we are today. 
We are continuing the effort to increase awareness of 
PBM practices, the role of the pharmacist on the 
healthcare team and the impact both have on the care 
of the patient. 
References 
1. State of New York Execu11ve Order No. 176, January 25. 2018. 
2. National Institute of Mental Health (2017). SchiLophrenia. Re-
trieved January 12, 2018, from https:IJWww.nimh.n1h.gov/health/ 
statistics/p1 evalence/schizoph1enia shtm1. 
3. 8rissos s, et al. The role of long-acting injectable antipsychot1cs 
in schizophrenia: a critical appraisal. Therapeutic Advances in 
Psychopharmacology. 2014; 4(5): 198-219. 
4. Geerts P. Attitudes towards the administration of long-acting 
antlpsychotics: a survey of physiclans and nurses. BMC Psych 
2013; 13:58. 
5. Potkin S. et al. Patient and prescriber perspectives on long-
acting injectable anbpsychotics and analysis of in-office discus· 
Sion regarding LAI treatment for schizophrenia. BMC Psych. 
2013; 13:261. 
6. http> //www cdc gov/druooverdose/lndex html 
7. Medications for Opioid Use Disorder. Treatment Improvement 
Protocol 63 SAMHSA 2018 
8. Report from the Stakeholder Group. State Policy Recommcnda· 
tions for Pharmacist Administration of Medications. March 2017 
9. love R. CPNP and NASPA lead Effort on long Acting Ant1psy-
chotic Injections. CPNP Perspective 2017, 4(3)· 4 
10. Kentucky Revised Statutes 315.010(22), accessed at h!!.Q;fL 
www Ire lsy gov/sratutP'>/starute aspx7td=46694 on Febr\Jary 23, 
2018. 
11. These are. California, Massachusetts, Montana, New Mexico, 
North Carolina, Ohio, and Washington. Idaho may soon join. 
hnps·//www.de;idiversion.usdojgov/drugreg/Qrac!loners/ 
min by ~tatf' pelt, accessed Februa1y 16, 2018 
Some of the more powerful pieces include: 
States Fight Back Against Unfair Prescription 
Pricing Pradires, (WNYT.com, March 5, 2018) 
Regulators Push to End Prescription Gag 
Clauses, (NBC News NY, February 27, 2018) 
Why Your Pharmacist Can't Tell You That $20 
Prescription Could Cost Only $8, (New York 
Times - February 25, 2018) 
To see the most recent coverage, please visit: 
PSSNY's Press Room: www.PSSNY.org/PressRoom. 
Please watch the website and your email inbox for 
breaking news on our legislative activities. Information 
can change quickly and often. The information in this 
article was accurate at the time the Journal went to press. 
